GlassScriptPhysician profile
Rebekah Cote
NPI 1487603742
$2,177.46
in general payments reported to CMS, 2019-2025
19 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $346 · 2021: $413 · 2022: $355 · 2023: $214 · 2024: $300 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,097.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $220.61 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $176.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $117.03 | 2021-2025 | Vraylar, Qulipta |
| Pfizer INC. | $103.43 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $71.61 | 2019-2021 | |
| Eisai INC. | $50.79 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.32 | 2020-2021 | |
| Exact Sciences Corporation | $32.17 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $28.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.15 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $18.21 | 2025 | Vaxneuvance, Capvaxive |
| Amarin Pharma, INC. | $17.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.08 | 2024 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14.21 | 2020 | |
| Dexcom, INC. | $13.46 | 2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $13.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.75 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Cote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.